Table 4.
Cohort studies of vitamin D exposure in relation to ovarian cancer survival.
| Author, Year of Publication [reference] |
Study Location | Follow-Up Years | Cohort Size | No. of Outcomes | Measure of Vitamin D | Measure of Association with Survival | Adjustment Variables | Study Quality 1 |
|---|---|---|---|---|---|---|---|---|
| Porojnicu, 2008 [33] | Norway | 1964–2000 | 42,096 | 7112 | Ultraviolet index based on residential region and season at diagnosis | RRs of death at 36 months were 1 for all region/season comparisons | Age, sex, birth cohort, stage of disease and UV index. | 8 |
| Walentowicz-Sadlecka, 2012 [34] |
Poland | 2005–2011 | 72 | Not mentioned | Circulating 25(OH)D on day of before surgery | Overall survival at 5 years for high vs low 25(OH)D, 46.3% vs 25.8%, respectively |
None | 3 |
| Webb, 2015 [35] |
Australia | 2002–2011 | 670 2 | 435 with disease progression or death | Circulating 25(OH)D at diagnosis | RR (95% CI): 0.93 (0.88, 0.99) per 10 nmol/L | Age, state of residence, smoking status at diagnosis and body mass index. | 8 |
| Webb, 2015 [35] |
Australia | 2002–2011 | 279 2 | 160 with disease progression or death | Circulating 25(OH)D after treatment (but before disease progression) | RR (95% CI): 0.97 (0.89, 1.06) per 10 nmol/L | Age, state of residence, smoking status at diagnosis and body mass index | 8 |
1 Score based on the Newcastle-Ottawa Scale; 2 Women with blood drawn at diagnosis and after treatment were analyzed separately.